PriceTargets.com logo

NASDAQ:ONTX - Onconova Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.52
  • Forecasted Upside: 132.01 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.65 As of 04/21/2021 01:00 AM ET
▲ +0.05 (8.28%)
1 month | 3 months | 12 months
Get New Onconova Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$1.52
▲ +132.01% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Onconova Therapeutics in the last 3 months. The average price target is $1.52, with a high forecast of $2.00 and a low forecast of $1.25. The average price target represents a 132.01% upside from the last price of $0.65.
Hold
The current consensus among 4 contributing investment analysts is to hold stock in Onconova Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/22/2020Noble FinancialUpgradeMarket Perform ➝ OutperformLow
i
Rating by Ahu Demir at Noble Financial
11/13/2020Maxim GroupReiterated RatingHoldMedium
i
Rating by Naureen Quibria at Maxim Group
8/25/2020Noble FinancialDowngradeOutperform ➝ Market PerformLow
i
Rating by Ahu Demir at Noble Financial
8/24/2020LaidlawDowngradeBuy ➝ HoldHigh
i
8/24/2020Maxim GroupDowngradeBuy ➝ HoldHigh
i
Rating by Naureen Quibria at Maxim Group
8/24/2020HC WainwrightDowngradeBuy ➝ NeutralN/A
i
Rating by Joseph Pantginis at HC Wainwright
8/13/2020Noble FinancialReiterated RatingBuy$1.30High
i
Rating by Ahu Demir at Noble Financial
8/3/2020Noble FinancialReiterated RatingBuyLow
i
Rating by Ahu Demir at Noble Financial
7/27/2020HC WainwrightReiterated RatingBuy$2.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
6/23/2020Maxim GroupInitiated CoverageBuy$1.25Medium
i
Rating by Naureen Quibria at Maxim Group
6/15/2020Noble FinancialReiterated RatingBuy$1.30Medium
i
Rating by Ahu Demir at Noble Financial
5/15/2020Maxim GroupUpgradeHold ➝ Buy$1.25High
i
Rating by Jason McCarthy at Maxim Group
3/25/2020HC WainwrightReiterated RatingBuyHigh
i
12/27/2019Noble FinancialReiterated RatingBuy$1.30High
i
Rating by Ahu Demir at Noble Financial
11/26/2019Maxim GroupDowngradeBuy ➝ HoldHigh
i
Rating by Jason McCarthy at Maxim Group
10/29/2019Noble FinancialReiterated RatingBuy$12.00High
i
9/9/2019Maxim GroupSet Price TargetBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
8/12/2019Maxim GroupSet Price TargetBuy$8.00Medium
i
Rating by Jason McCarthy at Maxim Group
7/25/2019Noble FinancialInitiated CoverageOutperform$12.00High
i
5/14/2019HC WainwrightSet Price TargetBuy$25.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
5/14/2019Maxim GroupReiterated RatingBuy$16.00High
i
Rating by Jason McCarthy at Maxim Group
3/26/2019HC WainwrightSet Price TargetBuy$25.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/25/2019Maxim GroupReiterated RatingBuy$16.00Low
i
Rating by Jason McCarthy at Maxim Group
2/8/2019HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Joseph Pantginis at HC Wainwright
12/3/2018HC WainwrightSet Price TargetBuy$25.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/3/2018Maxim GroupSet Price TargetBuy$16.00High
i
Rating by Jason McCarthy at Maxim Group
11/14/2018HC WainwrightSet Price TargetBuy$25.00High
i
Rating by Joseph Pantginis at HC Wainwright
11/13/2018Maxim GroupSet Price TargetBuy$16.00High
i
Rating by Jason McCarthy at Maxim Group
10/11/2018Maxim GroupLower Price TargetBuy$45.00 ➝ $16.00Medium
i
9/27/2018HC WainwrightReiterated RatingBuy$25.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
8/14/2018HC WainwrightSet Price TargetBuy$45.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/14/2018Maxim GroupReiterated RatingBuy$45.00High
i
Rating by Jason McCarthy at Maxim Group
5/15/2018HC WainwrightSet Price TargetBuy$45.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/2/2018Maxim GroupUpgradeHold ➝ BuyMedium
i
Rating by Jason McCarthy at Maxim Group
3/26/2018HC WainwrightSet Price TargetBuy$120.00Low
i
Rating by Joseph Pantginis at HC Wainwright
3/26/2018Maxim GroupReiterated RatingHoldLow
i
Rating by Jason McCarthy at Maxim Group
3/9/2018HC WainwrightReiterated RatingBuy$120.00Low
i
Rating by Joseph Pantginis at HC Wainwright
3/8/2018Maxim GroupReiterated RatingHoldLow
i
Rating by Jason McCarthy at Maxim Group
3/2/2018Maxim GroupReiterated RatingHoldMedium
i
Rating by Jason McCarthy at Maxim Group
3/1/2018HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $112.50Low
i
Rating by Joseph Pantginis at HC Wainwright
1/18/2018HC WainwrightReiterated RatingBuy$90.00High
i
Rating by Joseph Pantginis at HC Wainwright
1/17/2018Maxim GroupDowngradeBuy ➝ HoldHigh
i
Rating by Jason McCarthy at Maxim Group
1/4/2018HC WainwrightSet Price TargetBuy$90.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/19/2017HC WainwrightSet Price TargetBuy$90.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/12/2017HC WainwrightSet Price TargetBuy$90.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
11/9/2017HC WainwrightReiterated RatingBuyN/A
i
Rating by J. Pantginis at HC Wainwright
11/9/2017Maxim GroupSet Price TargetBuy$90.00N/A
i
Rating by Jason McCarthy at Maxim Group
11/2/2017Maxim GroupReiterated RatingBuy$90.00N/A
i
Rating by Jason McCarthy at Maxim Group
10/9/2017HC WainwrightInitiated CoverageBuy ➝ Buy$90.00N/A
i
Rating by J. Pantginis at HC Wainwright
8/15/2017Maxim GroupSet Price TargetBuy$90.00High
i
Rating by Jason McCarthy at Maxim Group
7/25/2017Dawson JamesReiterated RatingBuyHigh
i
Rating by R. Wasserman at Dawson James
6/6/2017Maxim GroupSet Price TargetBuy$90.00Medium
i
Rating by Jason McCarthy at Maxim Group
5/15/2017Maxim GroupSet Price TargetBuy$90.00Low
i
Rating by Jason McCarthy at Maxim Group
4/27/2017LaidlawInitiated CoverageBuy ➝ Buy$150.00Low
i
4/4/2017Maxim GroupReiterated RatingBuy$90.00High
i
Rating by Jason McCarthy at Maxim Group
3/27/2017Maxim GroupSet Price TargetBuy$90.00Low
i
Rating by Jason McCarthy at Maxim Group
9/26/2016Maxim GroupReiterated RatingBuy$90.00N/A
i
Rating by jason mccarthy at Maxim Group
8/19/2016Maxim GroupReiterated RatingBuy$90.00N/A
i
Rating by jason mccarthy at Maxim Group
8/11/2016Maxim GroupSet Price TargetBuy$90.00N/A
i
(Data available from 4/22/2016 forward)
Onconova Therapeutics logo
Onconova Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and a dose-escalation and expansion Phase 1 trial is planned in the U.S. The company's product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Read More

Today's Range

Now: $0.65
$0.59
$0.67

50 Day Range

MA: $0.96
$0.60
$1.25

52 Week Range

Now: $0.65
$0.19
$1.93

Volume

5,969,930 shs

Average Volume

45,762,633 shs

Market Capitalization

$154.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Onconova Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Onconova Therapeutics in the last twelve months: HC Wainwright, Laidlaw, Maxim Group, Noble Financial, and Zacks Investment Research.
View the latest analyst ratings for ONTX.

What is the current price target for Onconova Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Onconova Therapeutics in the last year. Their average twelve-month price target is $1.52, suggesting a possible upside of 132.0%. HC Wainwright has the highest price target set, predicting ONTX will reach $2.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $1.25 for Onconova Therapeutics in the next year.
View the latest price targets for ONTX.

What is the current consensus analyst rating for Onconova Therapeutics?

Onconova Therapeutics currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ONTX, but not buy more shares or sell existing shares.
View the latest ratings for ONTX.

What other companies compete with Onconova Therapeutics?

Other companies that are similar to Onconova Therapeutics include Albireo Pharma, KalVista Pharmaceuticals, OrganiGram, Relmada Therapeutics, Eagle Pharmaceuticals, SIGA Technologies, Crinetics Pharmaceuticals, Mirum Pharmaceuticals, Aldeyra Therapeutics, 89bio, IVERIC bio, CytomX Therapeutics, Magenta Therapeutics, Basilea Pharmaceutica and RAPT Therapeutics.

How do I contact Onconova Therapeutics' investor relations team?

Onconova Therapeutics' physical mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company's listed phone number is 267-759-3680 and its investor relations email address is [email protected] The official website for Onconova Therapeutics is www.onconova.com.